Company: CERO
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-044335
Chunk: 49

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 1
Chunk 49
---
 event.

During the three months ended
March 31, 2025, 625 Series A Preferred Warrants were exercised into 625 shares of Series A Preferred Stock for gross proceeds of $500,000.
During the three months ended March 31, 2024, no Series A Preferred Warrants were exercised into shares of Series A Preferred Stock.

The Company’s Preferred Warrants
were exercisable into Series A Preferred Stock, which had no cash redemption features that required liability treatment. The Company recorded
the Preferred Warrants as equity.

February 2025 Pre-funded Warrants and February
2025 Common Warrants

On February 5, 2025, in connection
with the February 2025 Offering (See Note 8), the Company sold (i) 300,000 shares of Common Stock, (ii) Pre-Funded Warrants to purchase
up to 2,251,020 shares of Common Stock, and (iii) Common Warrants to purchase up to 2,551,020 shares of common stock, at a combined public
offering price of $1.96 per share and Warrant. During the three months ended March 31, 2025, 1,824,280 shares of its common stock were
issued following the exercise of certain Pre-Funded Warrants. As of March 31, 2025, The remaining 426,740 Pre-Funded Warrants remain exercisable.

25

Additionally, in connection with the February 2025 Offering, the Company
issued the February 2025 Common Warrants to purchase up to 2,551,020 shares of common stock with an exercise price of $1.96 per share,
which are immediately exercisable upon stockholder approval and have a term of exercise equal to five years following date of the initial
exercise date. The exercise price and number of shares of Common Stock issuable upon exercise is subject to appropriate adjustment in
the event of stock dividends, stock splits, reorganizations or similar events affecting the Common Stock and the exercise price.

A summary of outstanding
warrants as of March 31, 2025 is as follows:

     Number of Warrants   Weighted Average Exercise Price   Weighted Average Remaining Contractual Life (in years)   Public and Private Placement Warrants   91,925   $1,150.00    3.88   February 2024 Series A Common Warrants   6,127    139.